Addressing lipid risk: a system-wide approach to implementation - PACE-CME

Addressing lipid risk a systemwide approach to implementation

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
AHA 2024
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Early and sustained non-HDL-c target achievement after MI
Early and sustained non-HDL-c target achievement after MI
Hyperlipidemia
Early and sustained non-HDL-c target achievement after MI
- Jessica Schubert, MD
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
MinuteCE®
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
0.75 program credits
- Pasquale Perrone-Filardi, MD, PhD
0.75 program credits